Literature DB >> 19878029

Synergistic increase in osteosarcoma cell sensitivity to photodynamic therapy with aminolevulinic acid hexyl ester in the presence of hyperthermia.

Shigeaki Yanase1, Jouji Nomura, Yoshihiko Matsumura, Yoshihiro Watanabe, Toshiro Tagawa.   

Abstract

OBJECTIVE: We observed that two osteosarcoma cell lines from the same tumor displayed marked differences in their sensitivities to photodynamic therapy (PDT) with aminolevulinic acid hexyl ester (hALA-PDT). We investigated why these two closely related lines had different hALA-PDT sensitivities and whether the PDT phototoxicity of the less sensitive cell line could be increased by a simultaneous application of hyperthermia (HT).
METHODS: Flow cytometry was used to evaluate the intracellular accumulation of protoporphyrin IX (PpIX), a metabolic product of aminolevulinic acid, in two human mandibular osteosarcoma cell lines (HOSM-1 and HOSM-2) treated with HT, hALA-PDT, or hALA-PDT combined with HT (PDT + HT). With hALA-PDT, cells treated with 0.2 mM hALA were irradiated with a light dose of 10-80 J/cm(2) from a near-infrared irradiator. With PDT + HT, the cells were treated as for hALA-PDT except that the temperature was raised to 43.5 degrees C during irradiation.
RESULTS: At 6 h after hALA treatment, HOSM-2 cells carried about 1.53-fold more PpIX than HOSM-1 cells. With hALA-PDT, the survival rate for HOSM-1 cells treated with 80 J/cm(2) irradiation was 35.7%, while that for HOSM-2 cells treated with 40-80 J/cm(2) was below 12%. With PDT + HT, the survival rate for HOSM-1 and HOSM-2 cells treated with 80 J/cm(2) irradiation was 14.1% and 10.7%, respectively.
CONCLUSION: A combination therapy comprising hALA-PDT + HT treatment may be very useful for the treatment of tumors containing cells that are insensitive to hALA-PDT, such as the HOSM-1 cell line described in this study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878029     DOI: 10.1089/pho.2008.2329

Source DB:  PubMed          Journal:  Photomed Laser Surg        ISSN: 1549-5418            Impact factor:   2.796


  6 in total

Review 1.  Intraoperative adjuncts for malignant pleural mesothelioma.

Authors:  Warren Ho Chan; David J Sugarbaker; Bryan M Burt
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma.

Authors:  Joseph S Friedberg
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Zinc phthalocyanines attached to gold nanorods for simultaneous hyperthermic and photodynamic therapies against melanoma in vitro.

Authors:  L F Freitas; M R Hamblin; F Anzengruber; J R Perussi; A O Ribeiro; V C A Martins; A M G Plepis
Journal:  J Photochem Photobiol B       Date:  2017-05-30       Impact factor: 6.252

4.  Hematoporphyrin monomethyl ether-mediated photodynamic therapy selectively kills sarcomas by inducing apoptosis.

Authors:  Hui Zeng; Mengxiong Sun; Chenghao Zhou; Fei Yin; Zhuoying Wang; Yingqi Hua; Zhengdong Cai
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

Review 5.  Progress of Phototherapy Applications in the Treatment of Bone Cancer.

Authors:  Jiachen Sun; Fei Xing; Joy Braun; Frank Traub; Pol Maria Rommens; Zhou Xiang; Ulrike Ritz
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

6.  Infrared-transparent gold nanoparticles converted by tumors to infrared absorbers cure tumors in mice by photothermal therapy.

Authors:  James F Hainfeld; Michael J O'Connor; Ping Lin; Luping Qian; Daniel N Slatkin; Henry M Smilowitz
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.